Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Voss

Showing results (221-230 of 419) with videos related to

Pageof 42
Sort By:
Frontiers in Chemistry|November 11, 2020
Sensitive LC-MS/MS Method for the Quantification of Macrocyclic Gα<sub>q</sub> Protein Inhibitors in Biological SamplesMarkus Kuschak, Jonathan G Schlegel, Marion Schneider, et al.
Molecular and Cellular Biology|July 22, 1998
Characterization of SRp46, a novel human SR splicing factor encoded by a PR264/SC35 retropseudogeneJ Soret, R Gattoni, C Guyon, et al.
The Lancet. Oncology|November 13, 2018
Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort studyMartin H Voss, Albert Reising, Yuan Cheng, et al.
Clinical Genitourinary Cancer|September 26, 2015
Bevacizumab Monotherapy as Salvage Therapy for Advanced Clear Cell Renal Cell Carcinoma Pretreated With Targeted DrugsChung-Han Lee, Andreas M Hötker, Martin H Voss, et al.
Communications Chemistry|June 1, 2023
Crystal structure of adenosine A<sub>2A</sub> receptor in complex with clinical candidate Etrumadenant reveals unprecedented antagonist interactionTobias Claff, Jonathan G Schlegel, Jan H Voss, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 25, 2014
Treatment outcome with mTOR inhibitors for metastatic renal cell carcinoma with nonclear and sarcomatoid histologiesM H Voss, D A Bastos, C A Karlo, et al.
Clinical Genitourinary Cancer|February 13, 2021
Genitourinary Medical Oncology Expert Opinion Survey Regarding Treatment Management in the COVID-19 PandemicMichal Sarfaty, Darren R Feldman, Michael J Morris, et al.
International Journal of Molecular Sciences|March 4, 2016
Dietary Apigenin Exerts Immune-Regulatory Activity in Vivo by Reducing NF-κB Activity, Halting Leukocyte Infiltration and Restoring Normal Metabolic FunctionHoracio Cardenas, Daniel Arango, Courtney Nicholas, et al.
ACS Pharmacology & Translational Science|April 16, 2021
Macrocyclic Gq Protein Inhibitors FR900359 and/or YM-254890-Fit for Translation?Jonathan G Schlegel, Mariam Tahoun, Alexander Seidinger, et al.
The Oncologist|June 12, 2016
A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell CarcinomaMaria I Carlo, Ana M Molina, Yulia Lakhman, et al.
Pageof 42

Showing results (221-230 of 419) with videos related to

Sort By:
Pageof 42
Frontiers in Chemistry|November 11, 2020
Sensitive LC-MS/MS Method for the Quantification of Macrocyclic Gα<sub>q</sub> Protein Inhibitors in Biological SamplesMarkus Kuschak, Jonathan G Schlegel, Marion Schneider, et al.
Molecular and Cellular Biology|July 22, 1998
Characterization of SRp46, a novel human SR splicing factor encoded by a PR264/SC35 retropseudogeneJ Soret, R Gattoni, C Guyon, et al.
The Lancet. Oncology|November 13, 2018
Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort studyMartin H Voss, Albert Reising, Yuan Cheng, et al.
Clinical Genitourinary Cancer|September 26, 2015
Bevacizumab Monotherapy as Salvage Therapy for Advanced Clear Cell Renal Cell Carcinoma Pretreated With Targeted DrugsChung-Han Lee, Andreas M Hötker, Martin H Voss, et al.
Communications Chemistry|June 1, 2023
Crystal structure of adenosine A<sub>2A</sub> receptor in complex with clinical candidate Etrumadenant reveals unprecedented antagonist interactionTobias Claff, Jonathan G Schlegel, Jan H Voss, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 25, 2014
Treatment outcome with mTOR inhibitors for metastatic renal cell carcinoma with nonclear and sarcomatoid histologiesM H Voss, D A Bastos, C A Karlo, et al.
Clinical Genitourinary Cancer|February 13, 2021
Genitourinary Medical Oncology Expert Opinion Survey Regarding Treatment Management in the COVID-19 PandemicMichal Sarfaty, Darren R Feldman, Michael J Morris, et al.
International Journal of Molecular Sciences|March 4, 2016
Dietary Apigenin Exerts Immune-Regulatory Activity in Vivo by Reducing NF-κB Activity, Halting Leukocyte Infiltration and Restoring Normal Metabolic FunctionHoracio Cardenas, Daniel Arango, Courtney Nicholas, et al.
ACS Pharmacology & Translational Science|April 16, 2021
Macrocyclic Gq Protein Inhibitors FR900359 and/or YM-254890-Fit for Translation?Jonathan G Schlegel, Mariam Tahoun, Alexander Seidinger, et al.
The Oncologist|June 12, 2016
A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell CarcinomaMaria I Carlo, Ana M Molina, Yulia Lakhman, et al.
Pageof 42